Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vistusertib is an orally bioavailable small molecule inhibitor of the mammalian target of rapamycin (mTOR), specifically acting as a dual inhibitor of both mTORC1 and mTORC2 complexes. By inhibiting mTOR, a serine/threonine kinase involved in the PI3K/Akt/mTOR signaling pathway, vistusertib can induce tumor cell apoptosis and decrease tumor cell proliferation. It was developed for potential antineoplastic activity across various cancers, including advanced gastric adenocarcinoma, breast cancer, ovarian cancer, lung cancer, renal carcinoma, diffuse large B-cell lymphoma, meningioma, and others. Vistusertib has demonstrated blood-brain barrier penetration and has been evaluated in combination with other therapies such as paclitaxel or aromatase inhibitors[1][2][3][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vistusertib.